Tsuneji Nagai
Overview
Explore the profile of Tsuneji Nagai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
401
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Hidaka S, Tokumura T, Tomono K, Suzuki T, Ueda H, Nagai T, et al.
Yakugaku Zasshi
. 2010 Jun;
130(6):889-93.
PMID: 20519868
The formation of an inclusion complex of amoxicillin (AMX) with beta-cyclodextrin (beta-CD) in aqueous solution was confirmed by a solubility method and proton nuclear magnetic resonance (1H-NMR) spectroscopy. The apparent...
3.
Li Y, Qi X, Maitani Y, Nagai T
Nanotechnology
. 2009 May;
20(5):055106.
PMID: 19417337
The purpose of this study was to characterize the properties in vitro, i.e. release, degradation, hemolytic potential and anticancer activity, and in vivo disposition of all-trans-retinoic acid (ATRA) in rats...
4.
Ma H, Xu Y, Qi X, Maitani Y, Nagai T
Int J Pharm
. 2008 Jan;
354(1-2):217-26.
PMID: 18191350
The objectives of this study were to describe the pharmacokinetics and tissue distribution of superparamagnetic iron oxide nanoparticle (SPIO) stabilized with alginate (SPIO-alginate), and investigate its potential in detecting liver...
5.
Ma H, Qi X, Ding W, Maitani Y, Nagai T
J Biomed Mater Res A
. 2007 Jul;
84(3):598-606.
PMID: 17618488
Ferrofluids are attractive candidates for magnetic targeting system because of their fluidity and magnetism. The magnetic nanoparticles in ferrofluids should have combined properties of superparamagnetic behavior, target localization, and biocompatibility....
6.
Zhang Y, Qi X, Gao Y, Wei L, Maitani Y, Nagai T
J Control Release
. 2007 Jan;
117(2):281-90.
PMID: 17196291
In order to deliver antisense oligonucleotides (asODN) into hepatocytes orientedly in the treatment of hepatitis B virus (HBV) infection, the liver-targeting cationic liposomes was developed as a gene carrier, which...
7.
Ma H, Qi X, Maitani Y, Nagai T
Int J Pharm
. 2006 Nov;
333(1-2):177-86.
PMID: 17074454
SPION with appropriate surface chemistry have been widely used experimentally for numerous in vivo applications. In this study, SPION stabilized by alginate (SPION-alginate) were prepared by a modified coprecipitation method....
8.
9.
Feng L, Qi X, Zhou X, Maitani Y, Wang S, Jiang Y, et al.
J Control Release
. 2006 Mar;
112(1):35-42.
PMID: 16516999
The objective of the study was to investigate the feasibility of a single-dose hepatitis B vaccine based on three kinds of poly (D, L)-lactide-co-glicolide acid (PLGA) microspheres. PLGA microspheres loaded...
10.
Shi J, Yan W, Qi X, Maitani Y, Nagai T
Drug Deliv
. 2005 Oct;
12(6):349-56.
PMID: 16253950
A novel cationic liposome modified with soybean sterylglucoside (SG) and polyethylene glycol-distearoylphosphatidylethanolamine (PEG-DSPE) as a carrier of antisense oligodeoxynucleotide (ODN) for hepatitis B virus (HBV) therapy was constructed. Characteristics of...